Becton Dickinson (NYSE:BDX) today priced a set of European debt offerings totaling $677 million. In the first offering, the Franklin Lakes, N.J.-based company issued $346.3 million (EU €300 million) in 1.401% notes due May 24, 2023 in a public offering between it and The Bank of New York Mellon Trust Company. Becton Dickinson said that it […]
Funding Roundup
Neurent Medical sniffs out $11m for rhinitis device
Neurent Medical reportedly sniffed out a funding round of nearly $12 million for the minimally invasive rhinitis treatment it’s developing. The €9.3 million round for Oranmore, Ireland-based Neurent was led by Irish venture capital shop Fountain Healthcare Partners and included participation from Atlantic Bridge, Ireland’s Western Development Commission, Enterprise Ireland and a syndicate of U.S. and Irish medical […]
Imricor raises $2m
Imricor Medical Systems has raised $1.5 million in a new round of debt and securities financing, according to an SEC filing posted this week. Money in the funding round came from 19 unnamed investors, with the date of the first sale reported on April 4, 2018. The company is not looking to raise any more money […]
Hancock Jaffe re-sets the range for $8m IPO
Medical device developer Hancock Jaffe Laboratories yesterday re-set the range on a pending initial public offering, which would fetch roughly $8 million at the midpoint. Irvine, Calif.-based Hancock Jaffe makes bioprosthetic implants designed to treat chronic deep vein insufficiency, heart valve conditions and coronary artery bypass graft. Last December the company said it planned to float nearly 1.9 million […]
RenovoRx raises $7m for drug-device pancreatic cancer therapy
RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer. The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds and others. […]
Tear Film Innovations closes $9m Series B
Eye-care focused device developer Tear Film Innovations said today it closed an $8.5 million Series B to support its flagship iLux system designed to treat blocked meibomian glands in eyelids. The iLux system is currently under investigational device review by the FDA, and is designed to allow for the in-office treatment of blocked meibomian glands through targeted […]
Electrocore registers $75m IPO
Electrocore yesterday registered for an initial public offering worth nearly $75 million, detailing plans to expand its GammaCore device beyond the two headache treatments it’s already cleared for in the U.S. The Basking Ridge, N.J.-based company said in a regulatory filing that it plans to use the $74.8 million IPO’s net proceeds to expand its sales […]
Access Vascular raises $2m
Access Vascular has raised $1.9 million in a new round of equity financing, according to an SEC filing posted this week. Money in the round came from seven unnamed sources, with the first sale recorded on May 4, according to the filing. The company is looking for an additional $2.1 million before it plans to close […]
NeuroVasc Tech raises $6m in Series B
NeuroVasc Technologies said yesterday it closed a $6.3 million Series B preferred stock round. The round was joined by multiple investors, and led by ShangBay Capital, the Laguna Hills, Calif.-based company said. NeuroVasc Tech is developing treatments for neurovascular conditions with a focus on treating ischemic stroke, and currently has CE Mark approval in the […]
Cerus lands additional $15m in government funding
Cerus (NSDQ:CERS) landed a $15 million amendment to its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and Development Authority, bringing the total potential value of its deal to $201 million. The expanded agreement is designed to support additional clinical trials of the company’s Intercept blood transfusion technology. Get the full […]
Integra LifeSciences closes $350m offering
Integra LifeSciences (NSDQ:IART) said yesterday it closed a $350 million offering of common stock, which included a fully exercised underwriter’s option. In the recently closed offering, the Plainsboro, N.J.-based company floated approximately 5.3 million shares of common stock at $58.50 per share. The offering included a 30-day underwriter’s option to purchase an additional 787,500 shares of common […]